烟台东诚药业集团股份有限公司 关于控股子公司获得放射性药品生产许可证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 近日，烟台东诚药业集团股份有限公司（以下简称"公司"）收到控股子公 司烟台蓝纳成生物技术股份有限公司（以下简称"蓝纳成"）的通知，通知其收 到山东省药品监督管理局下发的《放射性药品生产许可证》。相关信息如下： 一、基本情况 企业名称：烟台蓝纳成生物技术股份有限公司 统一社会信用代码：91310000MA1H3FYU34 注册地址：山东省烟台市牟平区东兴大街9号21号楼 证券代码：002675 证券简称：东诚药业 公告编号：2025-069 有效期至：2030年11月25日 二、对上市公司的影响及风险提示 本次蓝纳成取得《药品生产许可证》，预期不会对公司当前业绩产生重大影 响，氟[ 18F]思睿肽注射液待获得药品上市批准文号后可进行商业化生产。 由于医药产品具有高技术、高风险、高附加值等特点，药品销售易受行业政 法定代表人：罗志刚 企业负责人：吴晓明 质量负责人：周洪涛 许可证编号：鲁RS202502 策、市场环境变化等因素影响，敬请广大投 ...

Core Insights - Jiangsu Province has launched a special action to expand the first loan coverage for technology-based enterprises since 2025, addressing the "first loan difficulty" faced by innovative companies [1] - Nanjing Bank's Changzhou branch has successfully provided a first project loan to Qikangyuan Medical Technology (Changzhou) Co., Ltd., utilizing a multi-currency loan scheme to support the company's financial needs [1][2] Company Overview - Qikangyuan Medical Technology was established in 2021 with a registered capital of €40 million, co-owned by Dongcheng Nuclear Medicine and Germany's Eckert & Ziegler AG [1] - Dongcheng Pharmaceutical, a national high-tech enterprise, has multiple provincial innovation platforms and was recognized as a "Little Giant" enterprise by the Ministry of Industry and Information Technology in 2021 [1] - Eckert & Ziegler AG is a well-known supplier of isotopes for medical, scientific, and industrial applications, particularly strong in nuclear medicine imaging and cancer treatment [1] Industry Context - The company focuses on the research and production of medical radioactive isotopes and generators, which have historically relied on imports, leading to high costs and limited clinical application in China [1] - Changzhou has rapidly developed its medical device sector, forming a complete industrial chain that includes high-end medical equipment, in vitro diagnostics, and medical consumables, supported by policy initiatives and technological innovation [2] Financial Support - Nanjing Bank's Changzhou branch identified Qikangyuan's funding needs during a visit to companies on the "first loan expansion action" list and tailored a comprehensive financing solution based on the company's equity structure and growth trends [2] - The bank approved a medium- to long-term project loan of ¥180 million, with ¥46.08 million disbursed so far, easing the company's financial pressure for initial investments [2] - The successful loan issuance exemplifies the collaboration between government, banks, and enterprises to empower the real economy and enhance financial services for technology-based companies in Changzhou [2]

Investment Rating - The industry investment rating is "Outperform the Market" [1][31]. Core Viewpoints - The report highlights the initiation of centralized procurement for electrophysiology and neuro-interventional medical consumables in Beijing, which is expected to promote the entry of domestic high-end products and accelerate domestic substitution [4]. - The procurement covers all public medical institutions in Beijing, with a two-year agreement period, and includes various categories of electrophysiology and neuro-interventional products [4]. - The report suggests focusing on leading companies with comprehensive layouts in the electrophysiology field, such as Huatai Medical and Microelectrophysiology [4]. Summary by Sections Industry Overview - The centralized procurement for electrophysiology and neuro-interventional consumables has officially started, with a deadline for submission set for December 1 [4]. - The procurement is led by six top-tier hospitals in Beijing and aims to enhance the availability of domestic products [4]. Investment Strategy - The report recommends attention to innovative drug companies with rich pipeline layouts, such as Heng Rui Medicine, BeiGene, and China Biopharmaceuticals [6]. - It also highlights companies with significant single-product potential and those leading in advanced technology platforms [6]. Market Performance - The pharmaceutical sector saw a 2.67% increase last week, outperforming the CSI 300 index, which rose by 1.64% [9][20]. - In the Hong Kong market, the pharmaceutical sector increased by 3.85%, leading among 11 sectors [30]. Notable Industry News - Abbott announced a $21 billion acquisition of Exact Sciences, enhancing its position in the cancer diagnostics field [13]. - Johnson & Johnson is acquiring Halda Therapeutics for $3.05 billion, focusing on prostate cancer treatments [14]. - A significant ophthalmic drug has been approved for market release, expanding treatment options for age-related macular degeneration [16]. - Novartis received approval for its oral drug Remibrutinib in China, targeting chronic spontaneous urticaria [17].

Core Viewpoint - Dongcheng Pharmaceutical's subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., is developing a radiopharmaceutical for PET imaging in prostate cancer patients with PSMA-positive lesions [1] Group 1: Product Development - The product under development is Fluorine-18 labeled PSMA-targeted injection, aimed at diagnosing prostate cancer [1] - It is intended for patients who are candidates for initial radical treatment and those suspected of having metastatic lesions [1] - The drug is also applicable for patients with elevated serum PSA levels who are suspected of biochemical recurrence [1]

烟台东诚药业集团股份有限公司 关于氟[ 18F]思睿肽注射液完成 III 期临床试验的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、产品的基本情况 烟台东诚药业集团股份有限公司（以下简称"公司"）控股子公司烟台蓝纳 成生物技术股份有限公司（以下简称"蓝纳成"）正在研发的氟[ 18F]思睿肽注射 液是一种靶向 PSMA 的放射性体内诊断药物，适用于下述前列腺癌患者前列腺 特异性膜抗原（PSMA）阳性病灶的正电子发射断层扫描（PET）成像： （1）拟接受初始根治性治疗，怀疑存在转移灶的前列腺癌患者（以下简称 "初诊初治"）； 证券代码：002675 证券简称：东诚药业 公告编号：2025-068 二、III 期临床试验的基本情况 研究 18F-LNC1001-C002 是一项单臂、开放、多中心 III 期确证性临床试验， 用于评价氟[ 18F]思睿肽注射液 PET/CT 显像在拟接受前列腺癌根治性手术的患者 中检测盆腔淋巴结转移灶的诊断效能及安全性。研究 18F-LNC1001-C003 为一项 单臂、开放、多中心 III 期确证性临床试验，用于评价氟 ...

Core Viewpoint - Dongcheng Pharmaceutical announced that its subsidiary, Lanacheng, has completed two Phase III clinical trials for the fluorine-18 labeled peptide injection, demonstrating effective diagnostic performance and safety for prostate cancer patients [1] Group 1: Clinical Trial Results - The two studies, 18F-LNC1001-C002 and 18F-LNC1001-C003, targeted newly diagnosed and biochemically recurrent prostate cancer patients [1] - Both trials achieved preset goals in diagnostic efficacy, with specificity and sensitivity meeting the required standards [1] - No serious adverse reactions were reported during the trials [1] Group 2: Regulatory Actions - The company plans to submit a new drug application based on the successful trial results [1]

Group 1: Market Overview - Pluvicto has become a major topic in the nuclear medicine field, with sales projected to reach $1.392 billion in 2024, a 42% increase year-over-year [1] - The sales of Pluvicto for the first three quarters of this year reached $1.389 billion, reflecting a 33% year-over-year growth [1] - Novartis predicts that Pluvicto's peak sales will exceed $5 billion [1] Group 2: Competitive Landscape - Major pharmaceutical companies such as Eli Lilly, BMS, AstraZeneca, and Roche are actively entering the nuclear medicine market [2][5] - Domestic companies like Heng Rui and Chengdu Nuyret are also making significant strides in nuclear medicine research and development [2][6] - The market is experiencing a new wave of growth, particularly in radiolabeled drug conjugates (RDC) [2][5] Group 3: Clinical Developments - Novartis leads the nuclear medicine sector with multiple products, including Lutathera and Pluvicto, and is developing additional candidates like 177Lu-NeoB and 225Ac-PSMA-617 [5][6] - Several domestic companies have products in late-stage clinical trials, such as ITM-11 and NRT6003, targeting various cancers [6][11] - The clinical pipeline for 177Lu-based products is expanding, with 17 innovative drug products currently in clinical stages in China [9] Group 4: Supply Chain and Production - The supply chain for Lu-177 has seen significant improvements, with domestic production capabilities being established to meet market demand [13][14] - The launch of the core product Lu-177 by Hefu One on June 25, 2025, marks a major breakthrough in the domestic production of medical isotopes [13] - The integration of nuclear medicine production and supply chains is becoming more evident, particularly in regions like Sichuan and Haiyan [23] Group 5: Future Trends - Research is expanding into new alpha-emitting isotopes, with a focus on Ac-225, which has shown promise in treating various cancers [15][17] - The supply chain challenges for Ac-225 are more severe than those for Lu-177, with a significant gap between production and clinical demand [22] - The nuclear medicine sector is entering a new phase of rapid growth, driven by advancements in both research and production capabilities [24]

Core Insights - The article analyzes the changes in private equity fund holdings based on the top ten shareholders and circulating shareholders data, revealing significant shifts in stock positions among various sectors in Q3 2025 [1][2]. Private Equity Fund Holdings by Sector - In Q3 2025, the sectors with the highest number of stocks entering the top ten list by private equity managers were pharmaceuticals (18 stocks), basic chemicals (16 stocks), and electronics (15 stocks) [3]. - Compared to Q2 2025, there was an increase in stocks from the computer, pharmaceutical, and food and beverage sectors entering the top ten list, while the electronics, coal, and real estate sectors saw the most withdrawals [3]. Top 20 Stocks with Increased Holdings - The stocks with the highest increase in private equity fund holdings, measured by the proportion of total shares, predominantly came from the basic chemicals, pharmaceuticals, and electronics sectors [7]. - Notable stocks with the largest increase in private equity holdings included: - Darui Electronics (46.21% return) [8] - Zhongwei Co. (51.76% return) [8] - Guotou Power (−8.70% return) [8] - Yangjie Technology (34.64% return) [8] - Daqin Railway (−8.85% return) [8]. Top 20 Stocks with Decreased Holdings - The stocks with the largest decrease in private equity fund holdings were also concentrated in the pharmaceuticals, electronics, and basic chemicals sectors [9]. - Key stocks with the most significant reductions in private equity holdings included: - Lexin Technology (48.43% return) [9] - Dongcheng Pharmaceutical (5.63% return) [9] - Longbai Group (20.05% return) [9] - Zhenlei Technology (40.25% return) [9] - Shengxiang Biology (4.71% return) [9]. Individual Fund Manager Activities - Fund managers such as Ying Shui, Feng Liu, Ren Qiao, and others made notable adjustments to their portfolios in Q3 2025, increasing holdings in various stocks while reducing others [10][12][14][17][19][21]. - For instance, Feng Liu increased holdings in Zhongwei Co., Ruifeng New Materials, and Dongfulong while decreasing positions in Dongcheng Pharmaceutical and Longbai Group [12]. Summary of Fund Manager Adjustments - Ying Shui increased holdings in Xianle Health and reduced positions in Shengxiang Biology and Fangbang Co. [10]. - Feng Liu raised stakes in Zhongwei Co. and Ruifeng New Materials while cutting back on Dongcheng Pharmaceutical [12]. - Ren Qiao increased holdings in Jin Yu Medical and reduced positions in Xin Jing Dian and Xiao Fang Pharmaceutical [14]. - Other managers like Guo Feng Xinghua and Chongyang also adjusted their portfolios, increasing stakes in stocks like Guotou Power and Daqin Railway [17].

Group 1 - The report analyzes the changes in private equity fund holdings for the third quarter of 2025, highlighting the difficulty in obtaining direct data due to the lack of mandatory disclosures by private funds [1][9]. - The sectors with the highest number of stocks entering the top ten list by private equity managers in Q3 2025 are pharmaceuticals, basic chemicals, and electronics, with respective counts of 18, 16, and 15 [2][12]. - The report identifies the top 20 stocks with the highest increase in holding ratios by private equity managers, predominantly in the basic chemicals, pharmaceuticals, and electronics sectors [3][16]. Group 2 - The report provides a detailed analysis of the top 20 stocks with the largest increase in holding ratios, including stocks like Darui Electronics and Zhongwei Co., with respective increases of 2.41% and 2.29% [17]. - Conversely, the report lists the top 20 stocks with the largest decrease in holding ratios, with notable reductions in stocks such as Lexin Technology and Dongcheng Pharmaceutical, showing decreases of -2.20% and -2.12% respectively [19]. - The report also highlights specific private equity managers and their respective changes in stock holdings, such as Yingshui increasing its stake in Xianle Health and reducing its stake in Shengxiang Biology [20][24].

Core Viewpoint - Dongcheng Pharmaceutical (002675) emphasizes its commitment to comply with legal disclosure obligations and asserts that there are no undisclosed matters [1] Group 1 - The company responds to investor inquiries on November 26, indicating adherence to relevant laws and regulations regarding information disclosure [1] - Dongcheng Pharmaceutical will strictly follow the "Guidance No. 10 on Market Value Management for Listed Companies" to protect shareholder interests [1]